New type of non-opioid pain medication approved by FDA
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...
What to Know About Journavx, the Non-Opioid Pain Medication Just Approved by the FDA
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
Hosted on MSN2h
Non-Opioid Pain Medication Journavx Gets FDA Approval
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
Artificial intelligence can help detect congenital heart defects
AI-aided analysis of prenatal ultrasounds detected heart defects more quickly and accurately than doctors evaluating the ...
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.
Roche Gets FDA Approval for Breast Cancer Test
The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...
FDA approves first new non-opioid pain pill in decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...
ResMed stock drops despite earnings beat
The decline in stock value comes as analysts express mixed views on the company's quarterly performance. While ResMed achieved a 10% revenue increase compared to the same quarter last year, some ...
kffhealthnews7h
From KFF Health News - Latest Stories:
Cigna To Reform Prior Authorization, Provider Services In 2025 The Cigna Group will spend up to $150 million to reform its prior authorization, patient advocacy and provider services this year, CEO ...